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Left atrial (LA) stunning after cardioversion of atrialfibrillation (AF) has been reported during sponta-
neous conversion to sinus rhythm.1 This observation
suggest that atrial stunning is a function of underlying
arrhythmia and not of the mode of cardioversion. It is
known that AF causes atrial dilation, and progressive
LA enlargement occurs when AF becomes chronic.2
Recently, it has been shown that multiple factors con-
tribute to LA enlargement, including the presence and
persistence of arrhythmia.3 Many reports suggest that
if sinus rhythm is restored then dilation may regress.4
The Framingham Study showed a relation between
LA size and the risk of stroke in men and the risk of
death in both genders.5–7 Previous studies have sug-
gested that N-terminal atrial natriuretic peptide (N-
ANP) levels are elevated in patients with AF.8,9 It is
unclear whether AF rather than LA dilation,10 hemo-
dynamic impairment,11 or another hormonal alter-
ation, can result in the elevation of N-ANP levels.8
The present report evaluates the changes in LA size
and function after spontaneous cardioversion of AF
and their relation to N-ANP.
• • •
Hemodynamically stable patients referred for cardio-
version for nonrheumatic AF between September 1997
and March 2000 were considered for inclusion in this
investigation. The initial study group included 202 con-
secutive patients; 98 patients spontaneously recovered
sinus rhythm within 48 hours from the onset of arrhyth-
mia and were selected for the study (Group A). The
study population included 57 men and 41 women of
mean age 60  16 years; patients were compared with
98 age- and gender-matched control subjects (mean age
61  16 years) who underwent pharmacologic cardio-
version within 48 hours from the onset of arrhythmia
(Group B). Patients received intravenous propafenone 2
mg/kg of body weight; the drug was dissolved in 100 ml
of 5% glucose and infused over 30 minutes. Exclusion
criteria were: atrial flutter, valvular stenosis, valvular
prosthesis, significant valvular insufficiency, atrial and/or
left ventricular thrombosis, spontaneous echo contrast,
patent foramen ovale or an atrial septal aneurysm, or
decreased LV function (ejection fraction 45%). No
patients received long-term therapy with antiarrhythmic
drugs. Demographic and clinical characteristics of the
patients are listed in Table 1. Clinical records included
age, gender, time and circumstances of the onset of
symptoms related to AF, and the duration of AF esti-
mated from the initial onset of symptoms until the time
of the in-hospital conversion. The protocol was approved
by the Ethical Committee of our university and all pa-
tients signed an informed consent form.
The initial Doppler echocardiographic study was
performed during AF and after cardioversion (mean 3
 1.5 hours). A complete mono- and 2-dimensional
color Doppler echocardiogram was performed in each
patient using a commercial Hewlett-Packard echocar-
diograph (Andover, Massachusetts) with a 2.5-MHz
probe.
LA function was assessed using these parameters:
(1) transmitral pulsed Doppler recorded from the api-
cal 4-chamber view with the sample volume posi-
tioned between the tips of the mitral leaflets; peak
early filling (E) and atrial filling (A) velocities; and
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Age (yrs) 60  16 61  16
Men/women 57/41 58/40
Height (cm) 169  13 171  9
Weight (kg) 85  19 87  20
Body mass index (kg/m2) 26  3 25  2
Mean ventricular rate (beats/min) 98  24 97  26
Systemic hypertension 24 (24%) 29 (29%)
Diabetes mellitus 9 (9%) 10 (10%)
Coronary artery disease 3 (3%) 1 (1%)
Mean duration of AF (h) 27  10 29  9
FIGURE 1. LA border traced in the apical 4-chamber view; LA
volume calculated using Simpson’s formula.
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deceleration time and pressure halftime measured
from the transmitral flow pattern. (2) Atrial ejection
force was evaluated using this equation: 0.5   
mitral orifice area  (peak A velocity)2.12 Mitral
orifice area was assumed to be circular and was esti-
mated from the mitral annulus diameter as measured
from the apical 4-chamber view.
LA size was measured during systole along the
parasternal long-axis view from 2-dimensionally
guided M-mode tracing.13 LA volumes were deter-
mined at the mitral valve opening (maximal volume),
at the onset of atrial systole (P wave of electrocardio-
gram, P volume), and at mitral valve closure (minimal
volume). LA volumes were measured from the apical
4- and 2-chamber views by means of the biplane
area-length method, and corrected for body surface
area (Figure 1). 14 These parameters were estimated
from the LA volumes: LA passive emptying was
assessed as LA passive emptying volume (maximal
volume P volume), conduit volume (left ventricular
stroke volume  [maximal volume  minimal vol-
ume]), and LA passive emptying fraction (LA passive
emptying volume/maximal volume);
LA active emptying was estimated us-
ing LA active emptying volume (P
volume  minimal volume) and LA
active emptying fraction (LA active
emptying volume/P volume); LA total
emptying volume (maximal volume
 minimal volume); contribution of
passive emptying volume ([maximal
volume  P volume]/stroke volume),
of conduit volume (conduit volume/
stroke volume), and of active empty-
ing volume ([P volume  minimal
volume]/stroke volume) to left ven-
tricular stroke volume.15
Patients with moderate and severe
mitral regurgitation were excluded
from the study. All Doppler results
are mean measurements of 5 cardiac
cycles. The Doppler signal was ana-
lyzed using an IBM computer (Milan,
Italy).
Blood samples were collected in tubes that con-
tained ethylenediamine tetraacetic acid (7.5 mmol)
and a protease inhibitor (aprotinin). The plasma was
separated by centrifugation (2,500 rpm at 4°C) and
kept at 35°C until the determination of N-ANP
concentration by a radioimmunoassay technique. The
sensitivity of the method in our laboratory was 3
pg/ml, and inter- and intra-assay coefficients of vari-
ation were 16% and 14%, respectively.16
Data are expressed as mean 1 SD for continuous
variables. The statistical significance of serial changes
in echocardiographic parameters was determined by
the analysis of variance for repeated measures. Pear-
son’s correlation coefficient was used to study the
correlation between 2 parameters. The predictive
value of clinical and echocardiographic indexes for
spontaneous conversion was assessed with a logistic
regression analysis. The dependent variable was spon-
taneous conversion to sinus rhythm; covariates in-
cluded age, gender, time of onset of AF, duration of
arrhythmia, LA volumes, N-ANP, and atrial function.
TABLE 2 Serial Evaluation of Two-dimensional Echocardiographic Parameters Before and After Conversion to Sinus Rhythm in the









Heart rate (beats/min) 98  24 78  18* 97  26 69  20*
Systolic blood pressure (mm Hg) 134  22 129  12 138  24 130  20
Diastolic blood pressure (mm Hg) 90  10 87  11 89  13 88  9
ANP (ng/ml) 130  39 47  29* 122  15 51  23*
LA antero-posterior diameter (mm) 39  7 34  4* 41  3 39  6*
LA supero-inferior diameter (mm) 42  6 38  4* 44  5 40  6*
Maximal volume (cm3) 30  4 27  6* 35  5 30  6*
P atrial volume (cm3) 14  3 12  5* 18  5 14  6*
Minimal volume (cm3) 11  1.5 9  3.1 14  2 10  4
Conduit volume (cm3) 25  4 26  5 34  8 33  6
Passive emptying volume (cm3) 9  3.2 8  2.8 11  3.1 10  3.3
Active emptying volume (cm3) 6  2.4 7  3.1 7  2.1 6  2
*p 0.01.
CV  cardioversion.
FIGURE 2. Correlation between atrial ejection force (FEA) and N-ANP levels (Anp) in
patients with spontaneous conversion to sinus rhythm.
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Odds ratios and 95% confidence intervals were calcu-
lated based on results of the logistic regression anal-
ysis. A p value 0.05 was considered significant.
Mean duration of AF was 27  10 hours in Group
A and 29 9 hours in Group B (p NS). Mean heart
rate was higher in patients during AF compared with
that evaluated after conversion in the 2 groups of
patients. Systolic and diastolic blood pressures did not
change after conversion to sinus rhythm in either
group (Table 2). All patients had an adequate echo-
cardiogram.
The recovery of atrial mechanical function was
measured using peak A wave velocity and the atrial
ejection force. Atrial ejection force decreased in 56
patients after spontaneous restoration of sinus rhythm
(8.2  3 dynes) and was normal in the other patients
(11  3 dynes); it slightly decreased after pharmaco-
logic cardioversion (7 2 dynes). Serial evaluation of
atrial ejection force values and of peak A wave ve-
locities are listed in Table 2. An inverse correlation
was reported between atrial ejection
force and LA diameter (r  0.67, p
0.001 in Group A and r  0.56, p
0.01 in Group B). Patients with a
lower atrial ejection force had a larger
left atrium persisting after the recov-
ery of sinus rhythm.
The left atrium was enlarged in all
patients during arrhythmia. LA vol-
umes were greater during AF com-
pared with volumes recorded after the
restoration of sinus rhythm. Serial
evaluation of LA diameters and vol-
umes are listed in Table 2. N-ANP
was measured before and immedi-
ately after cardioversion. A compari-
son of hormonal levels between
groups showed that patients with
spontaneous conversion had signifi-
cantly higher N-ANP levels than pa-
tients of Group B during AF (312 
98 vs 245  87 pg/dl; p 0.001). A
comparison between groups in sinus
rhythm showed higher N-ANP levels
in patients with spontaneous conver-
sion even if the value was not signif-
icant (189  48 vs 145  54 pg/dl; p
 NS). A significant correlation was
found between atrial ejection force
and N-ANP level (r  0.73, p
0.001; Figure 2). A significant in-
verse correlation was observed be-
tween LA maximal volume and N-
ANP level (r  0.68; p 0.0001) in
patients with spontaneous conversion
to sinus rhythm, whereas the relation
with LA minimal volume was weak (r
 0.41, p 0.01; Figures 3 and 4).
Logistic regression analysis per-
mitted the identification of factors in-
fluencing spontaneous conversion to
sinus rhythm. No significant differ-
ences were observed concerning age, gender, or du-
ration of AF. Logistic regression analysis of echocar-
diographic data was used to identify predictors of
spontaneous conversion to sinus rhythm. The most
important predictor of spontaneous conversion was
the plasma concentration of N-ANP during the ar-
rhythmia; patients with levels of N-ANP over the
median value experienced spontaneous conversion
(odds ratio 3.20, 95% confidence interval 1 to 4.12).
Others predictors of spontaneous conversion were a
maximal volume of the left atrium 30 mm3 (odds
ratio 2.1, 95% confidence interval 1.1 to 3.0) and a
minimal volume 12 mm3 (odds ratio 1.5, 95% con-
fidence interval 0.9 to 4.0).
• • •
The present investigation shows that recovery of
atrial mechanical function was delayed in patients
with spontaneous conversion of AF. N-ANP levels
increased in patients with AF that spontaneously de-
veloped sinus rhythm compared with patients who did
FIGURE 3. Correlation between LA maximal volume and N-ANP levels (ANP) in pa-
tients with spontaneous conversion to sinus rhythm.
FIGURE 4. Correlation between LA minimal volume (Vol Min) and N-ANP levels
(Anp) in patients with spontaneous conversion to sinus rhythm.
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not spontaneously develop sinus rhythm. Spontaneous
conversion to sinus rhythm was associated with higher
values of N-ANP during AF and with smaller LA
volumes. This study evaluated the modification of LA
diameters and volumes during AF and after spontane-
ous conversion to sinus rhythm. Patients were com-
pared with a control group of subjects who underwent
successful pharmacologic cardioversion. We selected
patients who spontaneously reverted to sinus rhythm
to exclude interference on LA size due to atrial stun-
ning after cardioversion. In our experience, the recov-
ery of atrial mechanical function occurs promptly after
spontaneous conversion of AF.16,17 Mean duration of
AF in patients from our investigation was 36 hours,
suggesting that an early cardioversion of arrhythmia
can prevent atrial stunning. Nevertheless, a study by
Rubin and colleagues18 suggested that changes in the
LA anatomy and function occur quite soon after the
initiation of AF. Histologic changes are associated
with anatomic macroscopic changes (i.e., LA dilation
and changes in atrial volume and shape).13 The shape
of the left atrium is believed to be modified during
arrhythmia due to the loss of organized contraction.
These changes occurring in the atria during AF may
have a deleterious effect on the atria when sinus
rhythm is restored. The decrease of N-ANP levels
observed after cardioversion does not exclude the
possibility of atrial myocite alteration and may reflect
the transient inhibition of N-ANP secretion.8,19
The decrease of the supero-inferior diameter was
greater compared with decreases of the antero-poste-
rior and medio-lateral diameters. This feature suggests
a hemodynamic change in the left and right atrium due
to an increased mean right atrial pressure to maintain
an adequate left ventricular filling.
In conclusion, higher levels of N-ANP during
AF were independently associated with spontane-
ous conversion, as well as with smaller LA volume.
An inverse correlation existed between LA volume
and N-ANP.
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TABLE 3 Correlation Between Echocardiographic Parameters
and N-terminal Atrial Natriuretic Peptide (N-ANP)
Group A Group B
LA antero-posterior diameter r  0.26 r  0.48
p  NS p 0.05
LA supero-inferior diameter r  0.26 r  0.48
p  NS p 0.05
LA maximal volume r  0.68 r  0.40
p 0.0001 p 0.05
LA minimal volume r  0.41 r  0.21
p 0.01 p  NS
Left ventricular end-diastolic diameter r  0.26 r  0.29
p  NS p  NS
Left ventricular end-systolic diameter r  0.28 r  0.51
p  NS p 0.05
Left ventricular ejection fraction r  0.34 r  0.32
p  NS p  NS
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